Marianne Sinn
Experienced in Venous Thromboembolism (VTE)

Marianne Sinn

Hamburg, HH, DE 
Experienced in Venous Thromboembolism (VTE)
Hamburg, HH, DE 
OverviewLocationsClinical Research

Overview

Marianne Sinn practices in Hamburg, Germany. Ms. Sinn is rated as an Experienced expert by MediFind in the treatment of Venous Thromboembolism (VTE). Her top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Cholangiocarcinoma (Bile Duct Cancer), Pancreatectomy, and Pancreaticoduodenectomy.

Her clinical research consists of co-authoring 104 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 7 articles in the study of Venous Thromboembolism (VTE).

Gender
Female

Locations

Hamburg, HH, Germany
Other Locations
Eppendorf, HH, Germany
Berlin, BE, Germany
Konstanz, BW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial
Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial
Enrollment Status: Terminated
Publish Date: May 16, 2025
Intervention Type: Drug
Study Drug: Aspirin
Study Phase: Phase 3
Significance of Chemoradiation Following Induction Chemotherapy in Locally Advanced,Unresectable Pancreatic Cancer -a Randomised Phase 3 Trial: Chemoradiation Following Induction Chemotherapy Compared With Chemotherapy Alone
Significance of Chemoradiation Following Induction Chemotherapy in Locally Advanced,Unresectable Pancreatic Cancer -a Randomised Phase 3 Trial: Chemoradiation Following Induction Chemotherapy Compared With Chemotherapy Alone
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug, Radiation
Study Drugs: Gemcitabine, FOLFIRINOX
Study Phase: Phase 3
Adjuvant Immunotherapy in Patients With Resected Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): an Open Label Randomized Controlled Phase-2-study
Adjuvant Immunotherapy in Patients With Resected Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): an Open Label Randomized Controlled Phase-2-study
Enrollment Status: Active_not_recruiting
Publish Date: January 05, 2024
Intervention Type: Drug, Other
Study Drug: Nivolumab+Ipilimumab
Study Phase: Phase 2
View 2 Less Clinical Trials

104 Total Publications

Pancreatic Cancer Highlights from the European Society for Medical Oncology (ESMO) Annual Meeting 2024 in Barcelona.
Pancreatic Cancer Highlights from the European Society for Medical Oncology (ESMO) Annual Meeting 2024 in Barcelona.
Journal: Oncology research and treatment
Published: June 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Sinn's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile